KIF18A Inhibitors - New Opportunities in the Treatment of Chromosomally Unstable Tumors



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Chromosomal instability (CIN) is a hallmark of a wide range of malignant neoplasms and is characterized by an increased frequency of chromosome segregation errors during mitosis. Its presence correlates with aggressive clinical behavior, drug resistance, and reduced patient survival. At the same time, CIN creates a functional dependency of tumor cells on a limited number of regulatory pathways that maintain residual mitotic fidelity, providing a rationale for selective therapeutic intervention. In recent years, there has been growing interest in targeting components of the mitotic machinery that are critical under CIN conditions. One such target of ongoing research is the protein KIF18A, which is being considered as a potential therapeutic target in tumors with unstable karyotypes. This study aims to substantiate the therapeutic relevance of KIF18A in chromosomally unstable tumors and to review current experimental approaches to its inhibition, which are in preclinical and early clinical stages of development.

Full Text

Restricted Access

About the authors

Nikita S. Benderskii

Rostov State Medical University

Author for correspondence.
Email: cornance@yandex.ru
ORCID iD: 0000-0002-7636-1684
SPIN-code: 5966-0480

postgraduate

Russian Federation, 29, Nakhichevansky Lane, Rostov-on-Don, 344022, Russia

Anastasiya D. Ulyanova

Sechenov First Moscow State Medical University

Email: cornance@yandex.ru
ORCID iD: 0009-0006-6977-4452

student

Russian Federation, 8-2 Trubetskaya str. Moscow, Russian Federation, 119991

Anton A. Tsyganov

Russian University of Medicine

Email: cornance@yandex.ru
ORCID iD: 0009-0003-4092-7193

student

Russian Federation, 4, Dolgorukovskaya street, Moscow, 127006

Amaliya S. Golub

Russian University of Medicine

Email: cornance@yandex.ru
ORCID iD: 0009-0009-1289-3882

student

Russian Federation, 4, Dolgorukovskaya street, Moscow, 127006

Sergey I. Ponomarenko

Rostov State Medical University

Email: cornance@yandex.ru
ORCID iD: 0009-0009-6278-6495

student

Russian Federation, 29, Nakhichevansky Lane, Rostov-on-Don, 344022, Russia

Evgeniy A. Sergienko

Rostov State Medical University

Email: cornance@yandex.ru
ORCID iD: 0009-0009-2860-1645

student

Russian Federation, 29, Nakhichevansky Lane, Rostov-on-Don, 344022, Russia

Mariya V. Redko

Rostov State Medical University

Email: cornance@yandex.ru
ORCID iD: 0009-0001-8894-8650

student

Russian Federation, 29, Nakhichevansky Lane, Rostov-on-Don, 344022, Russia

Khati A. Azizova

Rostov State Medical University

Email: cornance@yandex.ru
ORCID iD: 0009-0001-6593-2285

student

Russian Federation, 29, Nakhichevansky Lane, Rostov-on-Don, 344022, Russia

Fatima Z. Dourbekova

Rostov State Medical University

Email: cornance@yandex.ru
ORCID iD: 0009-0008-9284-3852

student

Russian Federation, 29, Nakhichevansky Lane, Rostov-on-Don, 344022, Russia

Mekhrangez D. Nishonova

Russian University of Medicine

Email: cornance@yandex.ru
ORCID iD: 0009-0000-2655-9150

student

Russian Federation, 4, Dolgorukovskaya street, Moscow, 127006

Farzona B. Tursunova

Russian University of Medicine

Email: cornance@yandex.ru
ORCID iD: 0009-0004-4122-1763

student

Russian Federation, 4, Dolgorukovskaya street, Moscow, 127006

Ivetta K. Kokhanovskaya

Russian University of Medicine

Email: cornance@yandex.ru
ORCID iD: 0009-0002-0621-9612

student

Russian Federation, 4, Dolgorukovskaya street, Moscow, 127006

Dilafruz Kh. Rustamova

Russian University of Medicine

Email: cornance@yandex.ru
ORCID iD: 0009-0009-4296-5218

student

Russian Federation, 4, Dolgorukovskaya street, Moscow, 127006

Meristan R. Magomedova

Russian University of Medicine

Email: cornance@yandex.ru
ORCID iD: 0009-0002-8598-854X

student

Russian Federation, 4, Dolgorukovskaya street, Moscow, 127006

Roman D. Smeltsov

Russian University of Medicine

Email: cornance@yandex.ru
ORCID iD: 0009-0007-3613-6910

student

Russian Federation, 4, Dolgorukovskaya street, Moscow, 127006

Elza T. Ibakova

Rostov State Medical University

Email: cornance@yandex.ru
ORCID iD: 0009-0002-6672-1583

student

Russian Federation, 29, Nakhichevansky Lane, Rostov-on-Don, 344022, Russia

Anastasiya V. Podmareva

Rostov State Medical University

Email: cornance@yandex.ru
ORCID iD: 0009-0007-9110-492X

student

Russian Federation, 29, Nakhichevansky Lane, Rostov-on-Don, 344022, Russia

Amina R. Nazyrova

Rostov State Medical University

Email: cornance@yandex.ru
ORCID iD: 0009-0004-8082-9712

student

Russian Federation, 29, Nakhichevansky Lane, Rostov-on-Don, 344022, Russia

References

  1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2024;74(3):229–63. doi: 10.3322/caac.21834
  2. Zeidan A.M., Ridinger M., Lin T.L., Becker P.S., Schiller G.J., Patel P.A., et al. A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia. Clinical Cancer Research. 2020;26(23):6132–40. doi: 10.1158/1078-0432.ccr-20-2586
  3. Castellanos G, Valbuena DS, Pérez E, Villegas VE, Rondón-Lagos M. Chromosomal Instability as Enabling Feature and Central Hallmark of Breast Cancer. Breast Cancer: Targets and Therapy. 2023;15:189–211. doi: 10.2147/bctt.s383759
  4. Hosea R, Hillary S, Naqvi S, Wu S, Kasim V. The two sides of chromosomal instability: drivers and brakes in cancer. Signal Transduction and Targeted Therapy. 2024;9(1):75. doi: 10.1038/s41392-024-01767-7
  5. Yin L, Duan J.J., Bian X.W., Yu S. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Research. 2020;22(1):61. doi: 10.1186/s13058-020-01296-5
  6. Dolati E., Nourmohammadi J., Mesbahi H., Complications of Chemotherapy Drugs in the Process of Cancer Treatment: A Review Study, Eurasian Journal of Chemical, Medicinal and Petroleum Research. 2023; 2(5):57-62. https://doi.org/10.5281/zenodo.8073480
  7. Balik K, Modrakowska P, Maj M, Kaźmierski Ł, Bajek A. Limitations of molecularly targeted therapy. Medical Research Journal. 2019;4(2):99–105. doi: 10.5603/MRJ.a2019.0016
  8. Gupta S, Shukla S. Limitations of Immunotherapy in Cancer. Cureus. 2022;14(10):e30856. doi: 10.7759/cureus.30856
  9. Bhatia S, Khanna KK, Duijf PHG. Targeting chromosomal instability and aneuploidy in cancer. Trends in Pharmacological Sciences. 2024;45(3):210–24. doi: 10.1016/j.tips.2024.01.009
  10. Bach DH, Zhang W, Sood AK. Chromosomal Instability in Tumor Initiation and Development. Cancer Research. 2019 Aug 15;79(16):3995–4002. doi: 10.1158/0008-5472.CAN-18-3235
  11. Marquis C., Fonseca C.L., Queen K.A., Wood L., Vandal S.E., Malaby H.H., et al. Chromosomally unstable tumor cells specifically require KIF18A for proliferation. Nature Communications. 2021;12(1):1213. doi: 10.1038/s41467-021-21447-2
  12. Stumpff J., von Dassow G., Wagenbach M., Asbury C., Wordeman L.. The Kinesin-8 Motor Kif18A Suppresses Kinetochore Movements to Control Mitotic Chromosome Alignment. Developmental Cell. 2008;14(2):252–62. doi: 10.1016/j.devcel.2007.11.014
  13. Lin Y, Wei Y.L, She Z.Y. Kinesin-8 motors: regulation of microtubule dynamics and chromosome movements. Chromosoma. 2020;129(2):99-110. doi: 10.1007/s00412-020-00736-7
  14. Serpico AF, Pisauro C, Trano A, Grieco D. Chromosome alignment and Kif18A action rely on spindle-localized control of Cdk1 activity. Frontiers in Cell and Developmental Biology. 2024;12:1490781. doi: 10.3389/fcell.2024.1490781
  15. Mohd Amin A.S., Eastwood S., Pilcher C., Truong J.Q., Foitzik R., Boag J., et al. KIF18A inhibition: the next big player in the search for cancer therapeutics. Cancer and Metastasis Reviews. 2024;44(1):3. doi: 10.1007/s10555-024-10225-3
  16. Chen Q, Le X, Li Q, Liu S, Chen Z. Exploration of inhibitors targeting KIF18A with ploidy-specific lethality. Drug Discovery Today. 2024;29(10):104142. doi: 10.1016/j.drudis.2024.104142
  17. Tamayo N.A., Bourbeau M.P., Allen J.R., et al. Targeting the Mitotic Kinesin KIF18A in Chromosomally Unstable Cancers: Hit Optimization Toward an In Vivo Chemical Probe. J Med Chem. 2022;65(6):4972-4990. doi: 10.1021/acs.jmedchem.1c02030
  18. Locke J, Joseph AP, Peña A, Möckel MM, Mayer TU, Topf M, et al. Structural basis of human kinesin-8 function and inhibition. Proceedings of the National Academy of Sciences. 2017;114(45):E9539-E9548. doi: 10.1073/pnas.1712169114
  19. Cohen-Sharir Y, McFarland JM, Abdusamad M, Marquis C, Bernhard SV, Kazachkova M, et al. Aneuploidy renders cancer cells vulnerable to mitotic checkpoint inhibition. Nature. 2021;590(7846):486–91. doi: 10.1038/s41586-020-03114-6
  20. Quinton R.J., DiDomizio A., Vittoria M.A., et al. Whole-genome doubling confers unique genetic vulnerabilities on tumour cells. Nature. 2021;590(7846):492-497. doi: 10.1038/s41586-020-03133-3
  21. Gliech CR, Yeow ZY, Tapias-Gomez D, Yang Y, Huang Z, Tijhuis AE, et al. Weakened APC/C activity at mitotic exit drives cancer vulnerability to KIF18A inhibition. The EMBO Journal. 2024;43(5):666–94. doi: 10.1038/s44318-024-00031-6
  22. Luo W, Liao M, Liao Y, et al. The role of kinesin KIF18A in the invasion and metastasis of hepatocellular carcinoma. World J Surg Oncol. 2018;16(1):36. doi: 10.1186/s12957-018-1342-5
  23. Liu G, Cai G, He X, Huang D, Zhu G, Chen C, et al. KIF18A promotes head and neck squamous cell carcinoma invasion and migration via activation of Akt signaling pathway. Translational Cancer Research. 2019;8(6):2252–63. doi: 10.21037/tcr.2019.09.38
  24. Ren J, Yao X, Yang M, Cheng S, Wu D, Xu K, et al. Kinesin Family Member-18A (KIF18A) Promotes Cell Proliferation and Metastasis in Hepatocellular Carcinoma. Digestive Diseases and Sciences. 2024;69(4):1274–86. doi: 10.1007/s10620-024-08321-z
  25. Liao W, Huang G, Liao Y, Yang J, Chen Q, Xiao S, et al. High KIF18A expression correlates with unfavorable prognosis in primary hepatocellular carcinoma. Oncotarget. 2014;5(21):10271. doi: 10.18632/oncotarget.2082
  26. Zhang H, Shen T, Zhang Z, Li Y, Pan Z. Expression of KIF18A Is Associated with Increased Tumor Stage and Cell Proliferation in Prostate Cancer. Med Sci Monit. 2019;25:6418-6428. doi: 10.12659/MSM.917352
  27. Zhong Y, Jiang L, Lin H, et al. Overexpression of KIF18A promotes cell proliferation, inhibits apoptosis, and independently predicts unfavorable prognosis in lung adenocarcinoma. IUBMB Life. 2019;71(7):942-955. doi: 10.1002/iub.2030
  28. Savci-Heijink CD, Halfwerk H, Koster J, Horlings HM, van de Vijver MJ. A specific gene expression signature for visceral organ metastasis in breast cancer. BMC Cancer. 2019;19(1):333. doi: 10.1186/s12885-019-5554-z
  29. Phillips AF, Zhang R, Jaffe M, Schulz R, Carty MC, Verma A, et al. Targeting chromosomally unstable tumors with a selective KIF18A inhibitor. Nature Communications. 2025;16(1):307. doi: 10.1038/s41467-024-55300-z
  30. Payton M, Belmontes B, Hanestad K, Moriguchi J, Chen K, McCarter JD, et al. Small-molecule inhibition of kinesin KIF18A reveals a mitotic vulnerability enriched in chromosomally unstable cancers. Nature Cancer. 2023;5(1):66–84. doi: 10.1038/s43018-023-00699-5
  31. Lynes MM, Kahn S, Ghisolfi L, Dobrodziej J, Hotz T, Kim DH, et al. Abstract 3784: Activity of the novel KIF18A inhibitor, ATX-295, is enriched in whole genome doubled ovarian cancer pre-clinical models. Cancer Research. 2025;85(8):3784–3784. doi: 10.1158/1538-7445.am2025-3784
  32. Gaillard S, Starodub A, O'Neil B, et al. A phase I/II, first-in-human study of VLS-1488, an oral KIF18A inhibitor, in patients with advanced cancer [abstract]. J Clin Oncol. 2024;42(16 suppl):TPS3181. doi: 10.1200/JCO.2024.42.16_suppl.TPS3181
  33. Fonseca CL, Malaby HLH, Sepaniac LA, Martin W, Byers C, Czechanski A, et al. Mitotic chromosome alignment ensures mitotic fidelity by promoting interchromosomal compaction during anaphase. Journal of Cell Biology. 2019;218(4):1148–63. doi: 10.1083/jcb.201807228
  34. Nan K, Zhang L, Zou Y, Geng Z, Huang J, Peng Y, et al. Integrated Profiling Delineated KIF18A as a Significant Biomarker Associated with Both Prognostic Outcomes and Immune Response in Pancreatic Cancer. ImmunoTargets and Therapy. 2025; 14:123–38. doi: 10.2147/itt.s497284
  35. Sparling BA, Lee H, Zablocki MM, et al. Discovery of Kinesin KIF18A Inhibitor ATX020: Tactical Application of Silicon Atom Replacement. ACS Med Chem Lett. 2025;16(11):2309-2319. doi: 10.1021/acsmedchemlett.5c00512
  36. Nair J, Huang TT, Lynes M, Khan S, Silver S, Lee JM. The KIF18A Inhibitor ATX020 Induces Mitotic Arrest and DNA Damage in Chromosomally Instable High-Grade Serous Ovarian Cancer Cells. Cells. 2025;14(23):1863. doi: 10.3390/cells14231863
  37. Falchook GS, Bastida CC, Kurzrock R. Aurora Kinase Inhibitors in Oncology Clinical Trials: Current State of the Progress. Seminars in Oncology. 2015;42(6):832–48. doi: 10.1053/j.seminoncol.2015.09.022
  38. Gutteridge REA, Ndiaye MA, Liu X, Ahmad N. Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics. Molecular Cancer Therapeutics. 2016;15(7):1427–35. doi: 10.1158/1535-7163.mct-15-0897
  39. Martinez R, Blasina A, Hallin JF, Hu W, Rymer I, Fan J, et al. Mitotic Checkpoint Kinase Mps1 Has a Role in Normal Physiology which Impacts Clinical Utility. Rishi A, editor. PLOS ONE. 2015;10(9):e0138616. doi: 10.1371/journal.pone.0138616
  40. Robbrecht DGJ, Lopez J, Calvo E, He X, Hiroshi H, Soni N, et al. A first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumours. British Journal of Cancer. 2020;124(2):391. doi: 10.1038/s41416-020-01100-3
  41. Tardif K.D., Rogers A., Cassiano J., Roth B.L., Cimbora D.M., McKinnon R., et al. Characterization of the Cellular and Antitumor Effects of MPI-0479605, a Small-Molecule Inhibitor of the Mitotic Kinase Mps1. Molecular Cancer Therapeutics. 2011;10(12):2267. doi: 10.1158/1535-7163.mct-11-0453
  42. Zeidan AM, Ridinger M, Lin TL, Becker PS, Schiller GJ, Patel PA, et al. A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia. Clinical Cancer Research. 2020;26(23):6132–6140. doi: 10.1158/1078-0432.ccr-20-2586
  43. Konjikusic MJ, Gray RS, Wallingford JB. The developmental biology of kinesins. Dev Biol. 2021;469:26-36. doi: 10.1016/j.ydbio.2020.09.009
  44. Liu XS, Zhao XD, Wang X, et al. Germinal Cell Aplasia in Kif18a Mutant Male Mice Due to Impaired Chromosome Congression and Dysregulated BubR1 and CENP-E. Genes Cancer. 2010;1(1):26-39. doi: 10.1177/1947601909358184
  45. Wu T, Luo Y, Zhang M, et al. Mechanisms of minor pole-mediated spindle bipolarization in human oocytes. Science. 2024;385(6711):1022. doi: 10.1126/science.ado1022
  46. Wang H., Jia G. Minor poles, major impact: Insights into spindle bipolarization and female fertility. The Innovation Life. 2025; 3:100117. doi: 10.59717/j.xinn-life.2024.100117
  47. Mihajlović AI, Byers C, Reinholdt L, FitzHarris G. Spindle assembly checkpoint insensitivity allows meiosis-II despite chromosomal defects in aged eggs. EMBO Rep. 2023;24(11):e57227. doi: 10.15252/embr.202357227
  48. Biswas L, Tyc KM, Aboelenain M, et al. Maternal genetic variants in kinesin motor domains prematurely increase egg aneuploidy. Proc Natl Acad Sci U S A. 2024;121(45):e2414963121. doi: 10.1073/pnas.2414963121
  49. Tang F, Pan MH, Wan X, Lu Y, Zhang Y, Sun SC. Kif18a regulates Sirt2-mediated tubulin acetylation for spindle organization during mouse oocyte meiosis. Cell Div. 2018;13:9. Published 2018 Nov 10. doi: 10.1186/s13008-018-0042-4
  50. Czechanski A, Kim H, Byers C, Greenstein I, Stumpff J, Reinholdt LG. Kif18a is specifically required for mitotic progression during germ line development. Dev Biol. 2015;402(2):253-262. doi: 10.1016/j.ydbio.2015.03.011
  51. Liu T, Yang K, Chen J, Qi L, Zhou X, Wang P. Comprehensive Pan-Cancer Analysis of KIF18A as a Marker for Prognosis and Immunity. Biomolecules. 2023;13(2):326. doi: 10.3390/biom13020326
  52. Liu G, Zhang Y, Cao Z, Zhao Z. Targeting KIF18A triggers antitumor immunity and enhances efficiency of PD-1 blockade in colorectal cancer with chromosomal instability phenotype. Cell Death Discovery. 2025;11(1):2437. doi: 10.1038/s41420-025-02437-5
  53. Kim C, Wang XD, Yu Y. PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response. eLife. 2020;9:e60637. doi: 10.7554/elife.60637
  54. Musacchio L, Cicala CM, Camarda F, Ghizzoni V, Giudice E, Carbone MV, et al. Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon? ESMO Open. 2022;7(4):100536. doi: 10.1016/j.esmoop.2022.100536
  55. Leung JC, Cassimeris L. Reorganization of paclitaxel-stabilized microtubule arrays at mitotic entry: roles of depolymerizing kinesins and severing proteins. Cancer Biol Ther. 2019;20(10):1337-1347. doi: 10.1080/15384047.2019.1638678
  56. Weaver BA. How Taxol/paclitaxel kills cancer cells. Mol Biol Cell. 2014;25(18):2677-2681. doi: 10.1091/mbc.E14-04-0916
  57. Zasadil LM, Andersen KA, Yeum D, et al. Cytotoxicity of paclitaxel in breast cancer is due to chromosome missegregation on multipolar spindles. Sci Transl Med. 2014;6(229):229ra43. doi: 10.1126/scitranslmed.3007965
  58. Zhou AS, Tucker JB, Scribano CM, et al. Diverse microtubule-targeted anticancer agents kill cells by inducing chromosome missegregation on multipolar spindles. PLoS Biol. 2023;21(10):e3002339. doi: 10.1371/journal.pbio.3002339
  59. Hornick JE, Bader JR, Tribble EK, et al. Live-cell analysis of mitotic spindle formation in taxol-treated cells. Cell Motil Cytoskeleton. 2008;65(8):595-613. doi: 10.1002/cm.20283
  60. Mchedlishvili N, Matthews HK, Corrigan A, Baum B. Two-step interphase microtubule disassembly aids spindle morphogenesis. BMC Biol. 2018;16(1):14. Published 2018 Jan 23. doi: 10.1186/s12915-017-0478-z
  61. Leguay K, Decelle B, Elkholi IE, Bouvier M, Côté JF, Carréno S. Interphase microtubule disassembly is a signaling cue that drives cell rounding at mitotic entry. J Cell Biol. 2022;221(6):e202109065. doi: 10.1083/jcb.202109065
  62. Schuyler SC, Gupta R, Nguyen TTB, Weng CY, Chen HY. Small Molecules Identified by an In Silico Docking Screen Targeting Anaphase-Promoting Complex/Cyclosome Subunit 1 (APC1) Potentiate Paclitaxel-Induced Breast Cancer Cell Death. Molecules. 2025;30(4):895. doi: 10.3390/molecules30040895
  63. Vitale I, Galluzzi L, Castedo M, Kroemer G. Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol. 2011;12(6):385-392. doi: 10.1038/nrm3115
  64. Kawakami M, Mustachio LM, Liu X, Dmitrovsky E. Engaging Anaphase Catastrophe Mechanisms to Eradicate Aneuploid Cancers. Mol Cancer Ther. 2018;17(4):724-731. doi: 10.1158/1535-7163.MCT-17-1108
  65. Zhang C, Wu BZ, Thu KL. Targeting Kinesins for Therapeutic Exploitation of Chromosomal Instability in Lung Cancer. Cancers (Basel). 2025;17(4):685. doi: 10.3390/cancers17040685
  66. Kelley V, Baro M, Gasperi W, et al. Abstract B024: CRISPR-Cas9 screening reveals a novel JAK1 dependent mechanism of radioresistance in head and neck squamous cell carcinoma [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Translating Targeted Therapies in Combination with Radiotherapy; 2025 Jan 26–29; San Diego, CA. Philadelphia (PA): AACR; Clin Cancer Res. 2025;31(2 Suppl):B024. doi: 10.1158/1557-3265.TARGETEDTHERAP-B024
  67. Kelley VM, Baro M, Gasperi WE, et al. Loss of JAK1 Function Causes G2/M Cell Cycle Defects Vulnerable to KIF18A Inhibition. Cancer Res. 2026. doi: 10.1158/0008-5472.CAN-25-1423

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) Eco-Vector

License URL: https://eco-vector.com/for_authors.php#07
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия  ПИ № ФС 77 - 86296 от 11.12.2023 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 80632 от 15.03.2021 г.